Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ApexOnco Front Page
Recent articles
The company might have blown Enliven out of the water.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
The ESMO regular abstract lift reveals first human datasets for several projects.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
The group toplines a phase 2 win with Alphamedix.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
